Press-release for stocks related to iot

| 3.99% | O: 2.01% H: 1.1% C: 0.57%
pn-235 phase 2 phase 2b trial therapeutics psoriasis one biotech iot milestone plague

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

| -8.42% | O: -3.03% H: 3.21% C: 3.21%
SNY | News | $46.66 -2.16% -2.21% 1.7M

| -5.71% | O: 3.07% H: 0.0% C: 0.0%
thio-101 phase 2 technology trial approval australia biotech iot

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
Published: 2022-03-15 (Crawled : 12:00) - globenewswire.com
PDSB | $3.26 1.88% 1.84% 450K

| -37.01% | O: 0.2% H: 7.86% C: 7.27%
pds0101 phase 2 hpv trial cancer biotech iot tiona enroll

First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer
Published: 2022-03-10 (Crawled : 12:00) - prnewswire.com
VRAY | $0.025 -39.9% -61.87% 110M

| -99.37% | O: 1.01% H: 0.5% C: -1.75%
prostate cancer pos state trial therapy results cancer iot

New post-cryptogenic stroke remote telemetry study demonstrates increased atrial fibrillation detection and USD 4 million in cost savings using initial Philips BioTel Heart MCOT monitoring
Published: 2022-03-09 (Crawled : 10:00) - globenewswire.com
PHG | News | $20.97 -0.19% 0.0% 650K

| -28.8% | O: 6.4% H: 0.0% C: 0.0%
heart pos trial stroke iot

Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
EVAX | $4.06 -1.93% -1.97% 10K

| 44.25% | O: -0.7% H: 8.77% C: -2.81%
evx-02 trial phase 1 biotech iot phase 2 phase 3

Global Connected Consumer, Enterprise, and Industrial IoT Device Market Report 2022-2027: Device Ecosystem, Technology Enablers, Company Analysis, Future of Smart and Connected Devices
Published: 2022-03-04 (Crawled : 15:30) - prnewswire.com
LNVGF | $1.06 -28.71% 130K

| 0.0% | O: -2.84% H: 0.0% C: -2.9%
LNVGY | $21.14 -0.43% 22K

| -1.81% | O: -4.37% H: 0.0% C: -2.33%
NOKBF | News | $3.6 -2.55% 400

| -29.63% | O: -6.76% H: 3.44% C: 3.44%
ABLZF | News | $48.384 -32.74% 3K

Producer Manufacturing

| 40.89% | O: -5.77% H: 1.36% C: -5.59%
TCLRY | $0.001 1000.0% 140K

| -99.01% | O: -0.69% H: 0.8% C: 0.8%
WHR 4 | $105.68 0.27% 2.57% 1.7M

Consumer Durables

| -49.68% | O: -1.13% H: 0.0% C: 0.0%
ORCL | News | $115.34 0.22% -0.3% 5.2M

| 45.91% | O: -1.26% H: 0.0% C: 0.0%
NOK | News | $3.65 -0.82% 0.55% 13M

| -28.4% | O: -7.49% H: 0.0% C: 0.0%
HON | News 4 | $194.72 -0.73% -0.74% 3.4M

Producer Manufacturing

| 3.48% | O: -2.27% H: 0.0% C: 0.0%
DELL | News | $120.2 -0.36% -2.04% 5.8M

| 129.38% | O: -0.9% H: 0.0% C: 0.0%
ABB | News | $37.13 -0.03% 6.4M

Producer Manufacturing

| 10.18% | O: -5.43% H: 0.0% C: 0.0%
VUZI P | $1.33 1.53% 1.5% 670K

| -78.09% | O: -1.84% H: 0.0% C: 0.0%
POOL | $377.13 0.57% 0.57% 550K

Distribution Services

| -20.12% | O: -0.34% H: 0.0% C: 0.0%
MSFT | News 4 | $408.94 0.34% 0.33% 14M

| 34.57% | O: -2.83% H: 0.0% C: 0.0%
AAPL | $168.99 1.25% 1.24% 48M

| -0.91% | O: -2.32% H: 0.0% C: 0.0%
ces ce mark device technology trial system report smart iot

SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
Published: 2022-03-02 (Crawled : 12:00) - biospace.com/
SABS | $4.36 7.54% 730

| -9.54% | O: -14.32% H: 0.0% C: -33.17%
sab-185 covid-19 treatment trial therapeutics covid report phase 3 iot

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
Published: 2022-02-25 (Crawled : 19:00) - biospace.com/
CLVS | $0.0812 -3.94%

| -95.61% | O: 0.0% H: 0.0% C: 0.0%
fap-2286 ongoing trial imaging phase 1 therapy iot initiated

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
Published: 2022-02-25 (Crawled : 12:00) - biospace.com/
SABS | $4.36 7.54% 730

| -14.34% | O: 1.57% H: 0.0% C: 0.0%
sab-185 covid-19 treatment trial therapeutics covid phase 3 iot designation

Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
Published: 2022-02-18 (Crawled : 14:00) - biospace.com/
ATRA | $0.7101 -1.18% -1.2% 700K

| -94.74% | O: -14.04% H: 11.82% C: 11.56%
ata2271 trial therapeutics iot

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
Published: 2022-02-17 (Crawled : 14:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M

| 172.21% | O: 0.53% H: 2.65% C: -5.82%
gc012 car-t trial cel therapy biotech iot t-cell

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting
Published: 2022-02-16 (Crawled : 13:00) - globenewswire.com
SPRO | $1.41 -1.74% -1.77% 110K

| -85.57% | O: 2.1% H: 0.0% C: -5.69%
spr206 treatment xin drug trial therapeutics phase 1 topline results positive topline infection negative iot set infections

Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
Published: 2022-02-15 (Crawled : 15:30) - biospace.com/
LEGN | News | $45.205 -4.73% -4.97% 1.1M

| 19.46% | O: -4.15% H: 6.75% C: 6.65%
lb1901 clinical hold fda trial phase 1 biotech iot phase 2 phase 3

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer
Published: 2022-02-15 (Crawled : 14:30) - biospace.com/
PDSB | $3.26 1.88% 1.84% 450K

| -53.15% | O: 2.78% H: 4.42% C: -1.71%
pds0101 ces hpv trial cancer head and neck biotech iot

Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
MITO | $0.32 0.25%

| -48.88% | O: 0.64% H: 11.11% C: 3.16%
treatment phase 2 trial therapeutics iot

Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Published: 2022-02-15 (Crawled : 12:00) - prnewswire.com
VRAY | $0.025 -39.9% -61.87% 110M

| -99.43% | O: 3.4% H: 1.1% C: -7.24%
mridian prostate cancer state trial therapy cancer iot

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer
Published: 2022-02-02 (Crawled : 14:00) - biospace.com/
PDSB | $3.26 1.88% 1.84% 450K

| -47.37% | O: -8.22% H: 0.0% C: 0.0%
atile-002 keytruda phase 2 trial cancer biotech iot

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Published: 2022-02-02 (Crawled : 13:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

| -42.11% | O: 0.53% H: 0.0% C: 0.0%
biotech gastrointestinal trial phase 1 test positive cancer iot pancreatic

← Previous
1
2
3
4
5
6
7
Next →

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M

Consumer Services

BOF | $1.99 70.09% 41.21% 110M

ILAG | $0.51 6.03% 40.62% 1.7M

LICN | $0.941 68.04% 40.49% 15M

AMST | $3.31 65.5% 39.58% 70M

MTC | $3.615 61.38% 38.04% 9.3M

WIMI | $1.15 58.53% 36.92% 19M